BioCentury
ARTICLE | Clinical News

CNV2197944: Phase II started

April 29, 2013 7:00 AM UTC

Convergence Pharmaceuticals Ltd. (Cambridge, U.K.) began a double-blind, placebo-controlled Phase II trial to evaluate repeat doses of oral CNV2197944. As part of its restructuring in 2011, Convergen...